RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPT

Group 1 - The proposed sale of RAPT Therapeutics, Inc. to GSK plc involves shareholders receiving $58.00 in cash for each share of RAPT owned [1] - Kahn Swick & Foti, LLC is investigating whether the sale price adequately reflects the value of RAPT Therapeutics [1] - The transaction is structured as a tender offer, indicating that timing may be critical for shareholders [3] Group 2 - KSF is reaching out to shareholders who believe the transaction undervalues the company to discuss their legal rights [2] - Shareholders can contact KSF Managing Partner Lewis S. Kahn for more information regarding the proposed sale [2]